These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20848502)

  • 21. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.
    Dubinsky MC; Vasiliauskas EA; Singh H; Abreu MT; Papadakis KA; Tran T; Martin P; Vierling JM; Geller SA; Targan SR; Poordad FF
    Gastroenterology; 2003 Aug; 125(2):298-303. PubMed ID: 12891528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nodular regenerative hyperplasia of the liver secondary to azathioprine in a patient with inflammatory bowel disease.
    Bryant DL; Miles CJ; Gearry RB
    N Z Med J; 2010 Apr; 123(1313):74-6. PubMed ID: 20581898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
    Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
    Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mild changes of hepatic nodular regenerative hyperplasia may cause portal hypertension and be visible on reticulin but not hematoxylin and eosin staining.
    Navale P; Gonzalez RS
    Virchows Arch; 2021 Dec; 479(6):1145-1152. PubMed ID: 34435237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease.
    Geller SA; Dubinsky MC; Poordad FF; Vasiliauskas EA; Cohen AH; Abreu MT; Tran T; Martin P; Vierling JM; Targan SR
    Am J Surg Pathol; 2004 Sep; 28(9):1204-11. PubMed ID: 15316320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.
    Morris-Stiff G; White AD; Gomez D; Cameron IC; Farid S; Toogood GJ; Lodge JP; Prasad KR
    Eur J Surg Oncol; 2014 Aug; 40(8):1016-20. PubMed ID: 24370284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger.
    Grossman AB; Noble AJ; Mamula P; Baldassano RN
    Inflamm Bowel Dis; 2008 Jun; 14(6):750-5. PubMed ID: 18266236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease.
    López-Martín C; Chaparro M; Espinosa L; Bejerano A; Maté J; Gisbert JP
    Gastroenterol Hepatol; 2011; 34(6):385-92. PubMed ID: 21616565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis.
    Bermejo F; Lopez-Sanroman A; Taxonera C; Gisbert JP; Pérez-Calle JL; Vera I; Menchén L; Martín-Arranz MD; Opio V; Carneros JA; Van-Domselaar M; Mendoza JL; Luna M; López P; Calvo M; Algaba A
    Aliment Pharmacol Ther; 2008 Sep; 28(5):623-8. PubMed ID: 18513380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine.
    Buster EH; van Vuuren HJ; Zondervan PE; Metselaar HJ; Tilanus HW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Jan; 20(1):68-72. PubMed ID: 18090994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Nodular regenerative hyperplasia as a complication of thiopurine treatment in a patient with inflammatory bowel disease].
    Cohen-Ezra O; Avni Y; Morgenstern S; Ben-Ari Z
    Harefuah; 2012 Dec; 151(12):675-8, 721. PubMed ID: 23330258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine.
    Seksik P; Cosnes J; Sokol H; Nion-Larmurier I; Gendre JP; Beaugerie L
    Aliment Pharmacol Ther; 2009 May; 29(10):1106-13. PubMed ID: 19222411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients.
    van Asseldonk DP; Simsek M; de Boer NKH; Jharap B; Bloemena E; den Hartog G; Westerveld DB; Becx MC; Russel MG; Lissenberg-Witte BI; van Nieuwkerk CM; Mulder CJJ; Verheij J; van Bodegraven AA
    Scand J Gastroenterol; 2019 Jun; 54(6):753-760. PubMed ID: 31203688
    [No Abstract]   [Full Text] [Related]  

  • 34. Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: a prospective observational study.
    Al Rifai A; Prasad N; Shuttleworth E; McBurney H; Pushpakom S; Robinson A; Newman W; Campbell S
    Eur J Gastroenterol Hepatol; 2011 Feb; 23(2):153-8. PubMed ID: 21164349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
    Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
    Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing.
    Broekman MMTJ; Coenen MJH; van Marrewijk CJ; Wanten GJA; Wong DR; Verbeek ALM; Klungel OH; Hooymans PM; Guchelaar HJ; Scheffer H; Derijks LJJ; de Jong DJ;
    Inflamm Bowel Dis; 2017 Oct; 23(10):1873-1881. PubMed ID: 28644183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis.
    Russmann S; Zimmermann A; Krähenbühl S; Kern B; Reichen J
    Eur J Gastroenterol Hepatol; 2001 Mar; 13(3):287-90. PubMed ID: 11293451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
    Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrant von Willebrand factor expression of sinusoidal endothelial cells and quiescence of hepatic stellate cells in nodular regenerative hyperplasia and obliterative portal venopathy.
    Zhang X; Thomas C; Schiano TD; Thung SN; Ward SC; Fiel MI
    Histopathology; 2020 Jun; 76(7):959-967. PubMed ID: 31994248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study.
    Vos AC; Bakkal N; Minnee RC; Casparie MK; de Jong DJ; Dijkstra G; Stokkers P; van Bodegraven AA; Pierik M; van der Woude CJ; Oldenburg B; Hommes DW;
    Inflamm Bowel Dis; 2011 Sep; 17(9):1837-45. PubMed ID: 21830262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.